pharmacy

BMO upgraded the stock to "outperform" from "market perform," and lifted adjusted-earnings-per-share estimates to $2.89 and $3.30 for 2011 and 2012, respectively. The price target was set at $43, representing a target p/e multiple

CVS Caremark Corp. (CVS) jumped out of the gate and is holding most gains, up 2.5% in afternoon trading, on a boost from a BMO Capital Markets upgrade and raised full-year estimates this morning based on strong business fundamenta

However, the FDA did say it may at any time revisit a decision to exercise enforcement discretion, leaving some room open for future regulatory enforcement regarding compounding the drug, Reuters reported.

K-V Pharmaceuticals (KV.A) slides after the FDA says it does not plan to take enforcement action against pharmacies that compound KV.A's pre-term birth drug based on a valid prescription.

Sanofi-Aventis U.S., and its U.S. Consumer Healthcare Division, Chattem, announced that the FDA has approved the Allegra family of allergy medication products for over-the-counter, or OTC, use in adults and children two years of a

Morgan Stanley adjusted its 2011 and 2012 EPS estimates for Rite-Aid (NYSE:RAD) and maintained its underweight rating on the stock. The bank now sees a 2011 loss of $0.66 per share, a wider loss than its previous estimate for a lo